Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 27, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 2,000,000 ordinary shares.
- Repurchase Price: 1,138.4178 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.21% of total voting rights).
- Shares in Issue: 5,476,628,791 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,000,000 repurchased shares. Consequently, the total number of shares in issue stands at 5,476,628,791, which serves as the denominator for shareholder notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the updated share count of 5,476,628,791 for calculating ownership percentages and disclosure obligations.
- Confirm the total Treasury share holding of 504,194,158 shares and its impact on voting rights (9.21%).
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings.